AnaptysBio (ANAB) said Wednesday that it would discontinue further investment in experimental therapy ANB032 after a phase 2b trial in moderate-to-severe atopic dermatitis or eczema did not meet the primary and secondary endpoints.
The company said it would focus its resources and capital on its other investigational autoimmune drugs.
AnaptysBio said it expects to report top-line phase 2b data for rosnilimab in rheumatoid arthritis in February and top-line phase 2 data in ulcerative colitis in Q1 of 2026.
Shares of the company were up more than 2% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。